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background: Apixaban is the only novel oral anticoagulant which has demonstrated superiority to current standard of care (SoC) therapies including 
vitamin K antagonist (VKA) and aspirin through the ARISTOTLE and AVERROES trials, respectively. This analysis aimed to assess the potential clinical 
benefit associated with the lifetime use of apixaban versus SoC in patients with non-valvular atrial fibrillation (NVAF) in the United States (US).
methods: A Markov model was developed to extrapolate the observed clinical impact of apixaban versus VKA and aspirin to the lifetime horizon. 
Characteristics of the patient cohort (n = 1,000) entering the model were assumed to be similar to ARISTOTLE and AVERROES for comparisons to VKA 
and aspirin, respectively. Outcomes assessed included the number of clinical events avoided, number of patients needed to treat (NNT) to avoid one 
stroke, and number of patients needed to harm (NNH) with an additional major bleed. Key sources of inputs used to populate the model included: 
clinical event rates from ARISTOTLE and AVERROES; US life tables for life expectancy; and published literature for increased mortality related to 
events modeled.
results: Table 1: Projected Clinical Benefits of Treating with Apixaban versus SoC
For every 1,000 patient treated with apixaban over lifetime
Comparator






Number needed to 




Number needed to harm 
(NNH) over life-time
VKA 192 18 55 - 42 Dominant
Aspirin 325 57 18 38 26
conclusions: Based on the results projected by the model, lifetime use of apixaban, versus VKA as well as aspirin, is projected to increase life-
expectancy and provide substantial clinical benefit on stroke and major bleeding in patients with NVAF in the US.
